#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Xfsa

A new clinical trial is underway to assess the efficacy of two treatments, 2LEBV® and 2LXFS®, in reducing fatigue and other symptoms associated with Epstein-Barr Virus (EBV) infection. This randomized, placebo-controlled, double-blind study aims to provide valuable insights into managing the debilitating effects of EBV, particularly focusing on fatigue severity and other related symptoms. The trial will involve patients aged 12 and older who have been experiencing significant fatigue for at least one month, along with other EBV-related symptoms.

Table of Contents

What is SPECIFIC NUCLEIC ACID SNA-XFSA?

SPECIFIC NUCLEIC ACID SNA-XFSA is a medical substance being studied as a potential treatment for Epstein-Barr Virus (EBV) infection[1]. It is also known as “SNA-XFSa” or “SPECIFIC NUCLEIC ACID – CHRONIC FATIGUE SYNDROME TOXOPLASMA”[1]. This substance is classified as a nucleic acid, which means it’s related to the genetic material found in our cells.

SNA-XFSA is part of a medication called 2LXFS, which contains several other active substances, including other specific nucleic acids, proteins, and immune system modulators[1]. This combination of substances suggests that 2LXFS is designed to interact with the body’s immune system to potentially combat the Epstein-Barr Virus.

Target Condition: Epstein-Barr Virus Infection

The Epstein-Barr Virus (EBV) is a common virus that can cause various symptoms, including:

  • Fatigue
  • Fever
  • Sore throat
  • Swollen lymph nodes
  • Enlarged spleen

In some cases, EBV infection can lead to a condition called chronic fatigue syndrome, which is characterized by long-lasting exhaustion that doesn’t improve with rest[1].

Clinical Trial Overview

A clinical trial is currently being conducted to evaluate the effectiveness of 2LXFS (which contains SNA-XFSA) in treating fatigue associated with EBV infection[1]. This trial is:

  • Randomized: Participants are randomly assigned to different treatment groups
  • Placebo-controlled: Some participants receive a placebo (inactive substance) for comparison
  • Double-blind: Neither the participants nor the researchers know who is receiving the actual treatment or placebo

The main goal of this study is to compare the effectiveness of 2LXFS in reducing fatigue severity compared to a placebo[1].

Potential Benefits

While the effectiveness of SNA-XFSA is still being studied, the clinical trial aims to determine if it can help with:

  • Reducing fatigue severity[1]
  • Improving other symptoms related to EBV infection[1]
  • Positively affecting the immune system, as measured by changes in lymphocyte (a type of white blood cell) levels[1]

How is it Administered?

2LXFS, which contains SNA-XFSA, is administered in the form of pillules[1]. Pillules are very small pills, often used in homeopathic treatments. The medication is taken through oromucosal use, which means it’s applied to the mucous membrane of the mouth[1].

Who is Eligible for the Treatment?

The clinical trial has specific criteria for who can participate. Generally, eligible participants are:

  • 12 years of age or older
  • Experiencing significant fatigue for at least one month
  • Having at least two other symptoms related to EBV infection
  • Testing positive for EBV antibodies

However, there are also several conditions that would exclude someone from participating, such as recent use of certain medications or having specific health conditions[1].

Safety Considerations

As with any medical treatment, safety is a crucial concern. The clinical trial is monitoring for any adverse events (side effects) that may occur during the treatment[1]. It’s important to note that this medication is still being studied, and its full safety profile is not yet established.

Patients with certain conditions, such as galactose intolerance or glucose-galactose malabsorption syndrome, should not take this medication[1].

Aspect Details
Study Type Randomized, placebo-controlled, double-blind clinical trial
Treatments Evaluated 2LEBV® and 2LXFS®/2LEBV®
Primary Objective Evaluate efficacy in reducing fatigue severity in EBV patients
Secondary Objectives Assess impact on other EBV-related symptoms, lymphocyte typing, and antibody levels
Participant Age 12 years and older
Key Inclusion Criteria Significant fatigue for 1+ month, 2+ other EBV symptoms, positive EBV serology
Primary Endpoint General fatigue scale of MFI-20 questionnaire at 6 months
Treatment Duration 6 months, with follow-ups at 3 and 12 months
Safety Monitoring Occurrence of Adverse Events (AEs) and Severe Adverse Events (SAEs)

FAQ

  • What is the main goal of this clinical trial? The main goal is to compare the effectiveness of 2LEBV® and 2LXFS®/2LEBV® treatments versus a placebo in reducing fatigue severity in patients with Epstein-Barr Virus infection at the end of the treatment period.
  • Who can participate in this study? Patients aged 12 years and older who have been experiencing significant fatigue for at least one month, along with at least two other EBV-related symptoms, and have a positive EBV serology (IgG and/or IgM positive) can participate in the study.
  • How long does the treatment last? The main treatment period lasts for 6 months, with follow-up assessments at 3 months and 12 months to evaluate the long-term effects of the treatments.
  • What symptoms besides fatigue will be evaluated in this trial? The trial will assess various EBV-related symptoms, including exhaustion after light exertion, fever, loss of appetite, nausea, sore throat, muscle weakness, headaches, sleep disorders, and many others, to determine the treatments' effects on these symptoms.
  • How will the effectiveness of the treatments be measured? The primary measure will be the general fatigue scale of the MFI-20 questionnaire. Additionally, other scales of the MFI-20, EBV-related symptoms, lymphocyte typing, and antibody levels will be evaluated to assess the treatments' overall effectiveness.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Xfsa

  • Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Epstein-Barr Virus (EBV): A common virus that can cause infectious mononucleosis and is associated with certain cancers. It often leads to fatigue and other symptoms.
  • Asthenia: A medical term for weakness or lack of energy, which is a common symptom in EBV infections.
  • Serology: A blood test that looks for antibodies in your blood to determine if you have been exposed to or infected with a specific virus or bacteria.
  • IgG and IgM: Types of antibodies produced by the immune system. IgM antibodies usually appear early in an infection, while IgG antibodies are produced later and provide long-term immunity.
  • Lymphocyte typing: A test that identifies and counts different types of white blood cells (lymphocytes) in the blood, which can indicate how the immune system is functioning.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs to determine their effectiveness.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • MFI-20 questionnaire: A tool used to measure fatigue in patients, assessing various aspects such as general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lebv-and-2lxfs-for-reducing-fatigue-in-patients-with-epstein-barr-virus-infection/